News | Structural Heart Occluders | February 15, 2017

UAB First in Alabama to Implement New FDA-Approved Amplatzer PFO Occluder

Device reduces risk of recurrent ischemic stroke for 25 to 30 percent of Americans who have a patent foramen ovale

University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation

February 15, 2017 — Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-approved patent foramen ovale occluder in Alabama. 

A PFO is a hole in the heart that does not close the way it should after birth. During fetal development, a small flap-like opening — the foramen ovale — is normally present in the wall between the right and left upper chambers of the heart. It normally closes during infancy. With the new Amplatzer PFO Occluder, ischemic stroke patients will now have access to a closure device shown to reduce risk of recurrent stroke, rather than relying on medical management alone. 

Baker-Dean Endowed Professor in Interventional Cardiology Massoud Leesar, M.D., performed the first procedure Jan. 25, 2017. 

“This new device has the potential to help many patients who suffer from PFO and stroke,” he said. “Our first patient did very well and was discharged the day after the procedure since the echocardiogram showed complete closure of PFO.” 

Approximately 25 to 30 percent of Americans have a PFO, which typically causes no health problems and does not require treatment. The cause of most strokes can be identified, such as poorly controlled high blood pressure, narrowed blood vessels due to cholesterol deposits and scar tissue (atherosclerosis), or a blood clot caused by an abnormal heart rhythm (atrial fibrillation).

“Stroke in patients younger than 60 years old is most likely related to PFO,” Leesar said. “In patients older than 60, other causes such as atherosclerosis and atrial fibrillation will need to be ruled out. These patients are typically referred by neurologists who cannot define other causes for stroke.” 

The Amplatzer PFO Occluder is inserted through a catheter that is placed in a leg vein and advanced to the heart. It is then implanted close to the hole in the heart between the right atrium and the left chamber. The procedure is minimally invasive, and recovery time is minimal.

Nearly 795,000 new or recurrent strokes occur every year in the United States, making it the fifth-leading cause of death and leading cause of serious long-term disability for Americans, according to the American Heart Association. Ischemic strokes account for 87 percent of strokes, and occur when a blood vessel is obstructed, depleting the brain of its blood supply.

The Amplatzer PFO Occluder is developed by St. Jude Medical Inc.

For more information: www.sjm.com 

Related Content

Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Overlay Init